BridgeMD
New treatment option for Advanced Colorectal Cancer
Official title FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients
ClinicalTrials.gov ID: NCT07558083
What this study is testing
- What it's testing
- The FOLICOLOR trial aims to evaluate whether a liquid biopsy-guided follow-up strategy can improve outcomes in patients with unresectable, metastatic colorectal cancer (mCRC) receiving first-line systemic treatment. The approach uses NPY methylation-based circulating tumor DNA (ctDNA) analysis from blood samples to monitor treatment response and guide clinical decision-making.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Man or woman ≥ 18 years of age at the time the informed consent is obtained
- ECOG performance status of 0-2
- Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in people with unresectable metastatic (M1) disease
- There should be at least 1 uni-dimensionally measurable (min. 10mm) using conventional crosssectional imaging techniques (CT or MRI scan). Lesion...
- Adequate hematology, renal, hepatic and coagulation function (at treating physician's discretion)
You likely can't join if
- History of prior or concurrent central nervous system metastases
- History of other malignancy, except: Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to...
- Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab...
- Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab...
- Radiotherapy ≤ 14 days prior to randomization. people must have recovered from all radiotherapy-related toxicities.
See the full eligibility criteria
- Man or woman ≥ 18 years of age at the time the informed consent is obtained
- ECOG performance status of 0-2
- Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in people with unresectable metastatic (M1) disease
- There should be at least 1 uni-dimensionally measurable (min. 10mm) using conventional crosssectional imaging techniques (CT or MRI scan). Lesion must not be chosen from a previously irradiated field, unlessnthere has...
- Adequate hematology, renal, hepatic and coagulation function (at treating physician's discretion)
- Adequate blood results for treatment (at treating physician's discretion)
- Starting a first line treatment
- History of prior or concurrent central nervous system metastases
- History of other malignancy, except: Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by the treating...
- Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib...
- Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib...
- Radiotherapy ≤ 14 days prior to randomization. people must have recovered from all radiotherapy-related toxicities.
The study team makes the final eligibility decision.
Where it's taking place
- Mechelen, Antwerpen, Belgium
- Brasschaat, Antwerp, Belgium
- Edegem, Antwerp, Belgium
- Wilrijk, Antwerp, Belgium
- Charleroi, Henegouwen, Belgium
- Ghent, Oost-Vlaanderen, Belgium
- Sint-Niklaas, Oost-Vlaanderen, Belgium
- Bruges, West-Vlaanderen, Belgium
- Kortrijk, West-Vlaanderen, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mechelen, Antwerpen, Belgium; Brasschaat, Antwerp, Belgium; Edegem, Antwerp, Belgium; Wilrijk, Antwerp, Belgium; Charleroi, Henegouwen, Belgium; Ghent, Oost-Vlaanderen, Belgium and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.